Will Tesla Stock Go Up In 2026?
EV giant Tesla (NASDAQ:TSLA) has, somewhat surprisingly, undershot the broader…
Sell
49
TARA Quote, Financials, Valuation and Earnings
Last price:
$5.48
Seasonality move
:
27.06%
Day range:
$5.46 - $5.80
52-week range:
$2.77 - $7.82
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.66x
Volume:
700.5K
Avg. volume:
1M
1-year change:
-8.03%
Market cap:
$219.9M
Revenue:
--
EPS (TTM):
-$1.44
Analysts' Opinion
-
Consensus RatingProtara Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $25.00, Protara Therapeutics, Inc. has an estimated upside of 338.6% from its current price of $5.50.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $21.00 representing 100% downside risk from its current price of $5.50.
Fair Value
-
According to the consensus of 6 analysts, Protara Therapeutics, Inc. has 338.6% upside to fair value with a price target of $25.00 per share.
TARA vs. S&P 500
-
Over the past 5 trading days, Protara Therapeutics, Inc. has overperformed the S&P 500 by 2.79% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Protara Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Protara Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Protara Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Protara Therapeutics, Inc. has grown year-over-year earnings for 6 quarters straight. In the most recent quarter Protara Therapeutics, Inc. reported earnings per share of -$0.31.
Enterprise value:
90.9M
EV / Invested capital:
0.67x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.86x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$614K
Return On Assets:
-35.47%
Net Income Margin (TTM):
--
Return On Equity:
-38.66%
Return On Invested Capital:
-37.51%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$678K | -$357K | -$614K | -$84K | -$88K | |
| Operating Income | -$42.6M | -$45.9M | -$59.8M | -$12.3M | -$14.8M | |
| EBITDA | -$41.9M | -$45.5M | -$59.2M | -$12.2M | -$14.7M | |
| Diluted EPS | -$6.13 | -$2.82 | -$1.44 | -$0.50 | -$0.31 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $95.7M | $98.7M | $77.8M | $85.1M | $135.6M | |
| Total Assets | $180.7M | $148.6M | $88.5M | $94.1M | $144.6M | |
| Current Liabilities | $3.7M | $3.7M | $6.8M | $8.6M | $9.9M | |
| Total Liabilities | $10.3M | $9.4M | $11.5M | $12.3M | $12.3M | |
| Total Equity | $170.4M | $139.2M | $77M | $81.8M | $132.3M | |
| Total Debt | $7.4M | $5.7M | $4.7M | $3.7M | $2.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$33.9M | -$35.2M | -$48.7M | -$8.4M | -$12.5M | |
| Cash From Investing | $20.2M | $11.2M | -$90.1M | -$29.4M | -$6.5M | |
| Cash From Financing | -$91K | $42M | $99.6M | -- | $13K | |
| Free Cash Flow | -$33.9M | -$35.3M | -$48.8M | -$8.4M | -$12.5M | |
TARA
Sector
Market Cap
$219.9M
$29M
Price % of 52-Week High
72.89%
52.89%
Dividend Yield
0%
0%
Shareholder Yield
-59.29%
-1.4%
1-Year Price Total Return
-8.8%
-19%
Beta (5-Year)
1.385
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$5.86
200-day SMA
Buy
Level
$4.03
Bollinger Bands (100)
Buy
Level
3.17 - 5.85
Chaikin Money Flow
Buy
Level
6.8M
20-day SMA
Sell
Level
$6.45
Relative Strength Index (RSI14)
Sell
Level
43.84
ADX Line
Sell
Level
26.85
Williams %R
Neutral
Level
-77.0909
50-day SMA
Sell
Level
$5.66
MACD (12, 26)
Buy
Level
0.09
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Sell
Level
-342.5K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.0349)
Sell
CA Score
(Annual)
Level (-0.3121)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (3.9722)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.
Stock Forecast FAQ
In the current month, TARA has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TARA average analyst price target in the past 3 months is $25.00.
-
Where Will Protara Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Protara Therapeutics, Inc. share price will rise to $25.00 per share over the next 12 months.
-
What Do Analysts Say About Protara Therapeutics, Inc.?
Analysts are divided on their view about Protara Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Protara Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $21.00.
-
What Is Protara Therapeutics, Inc.'s Price Target?
The price target for Protara Therapeutics, Inc. over the next 1-year time period is forecast to be $25.00 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is TARA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Protara Therapeutics, Inc. is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TARA?
You can purchase shares of Protara Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Protara Therapeutics, Inc. shares.
-
What Is The Protara Therapeutics, Inc. Share Price Today?
Protara Therapeutics, Inc. was last trading at $5.48 per share. This represents the most recent stock quote for Protara Therapeutics, Inc.. Yesterday, Protara Therapeutics, Inc. closed at $5.50 per share.
-
How To Buy Protara Therapeutics, Inc. Stock Online?
In order to purchase Protara Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get TARA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
TARA
Sector
P/E ratio
--
24.19x
PEG ratio
--
-0.01x
P/B ratio
1.66x
1.84x
Price / LTM sales
--
1.61x
Growth Metrics
TARA
Sector
Revenue growth
--
4.6%
Earnings growth
37.58%
10.88%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.39
-$0.20
Profitability
TARA
Sector
Profitability FY 2024
-$332K
$3.5M
Return on invested capital
-37.51%
-31.66%
Return on assets
-35.47%
-27.84%
Return on equity
-38.66%
-37.15%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Mar
5
Estimated Next Earnings Date
Feb
9
Balance Sheet
TARA
Sector
Total cash
$132.7M
$26.8M
Short term investments
$7.5M
$26M
Total assets
$181.5M
$79.7M
Long term debt
$2.4M
$3.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
71
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
37
OKLO alert for Dec 16
Oklo, Inc. [OKLO] is down 5.81% over the past day.
Sell
43
SEI alert for Dec 16
Solaris Energy Infrastructure, Inc. [SEI] is down 5.3% over the past day.
Sell
39
SMX alert for Dec 16
SMX (Security Matters) Plc [SMX] is down 21.85% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
